Search Results

There are 14081 results for: content related to: Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance

  1. You have free access to this content
    JSH Guidelines for the Management of Hepatitis B Virus Infection

    Hepatology Research

    Volume 44, Issue S1, January 2014, Pages: 1–58, Drafting Committee for Hepatitis Management Guidelines and the Japan Society of Hepatology

    Version of Record online : 7 JAN 2014, DOI: 10.1111/hepr.12269

  2. You have free access to this content
    Efficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis BB

    Hepatology

    Volume 29, Issue 3, March 1999, Pages: 889–896, Nicolaos C. Tassopoulos, Riccardo Volpes, Giuseppe Pastore, Jenny Heathcote, Maria Buti, Robert D. Goldin, Sasha Hawley, Judy Barber, Lynn Condreay and D. Fraser Gray

    Version of Record online : 30 DEC 2003, DOI: 10.1002/hep.510290321

  3. Should lamivudine monotherapy be stopped or continued in patients infected with hepatitis B with favorable responses after more than 5 years of treatment?

    Journal of Medical Virology

    Volume 85, Issue 1, January 2013, Pages: 34–42, Jung Hyun Kwon, Jeong Won Jang, Jong Young Choi, Chung-Hwa Park, Sun Hong Yoo, Si Hyun Bae and Seung Kew Yoon

    Version of Record online : 14 NOV 2012, DOI: 10.1002/jmv.23421

  4. Management of viral hepatitis B

    Journal of Gastroenterology and Hepatology

    Volume 17, Issue s1, February 2002, Pages: S125–S145, CHUTIMA PRAMOOLSINSUP

    Version of Record online : 8 MAY 2002, DOI: 10.1046/j.1440-1746.17.s1.3.x

  5. Clinical and virological characteristics of lamivudine resistance in chronic hepatitis B patients: A single center experience

    Journal of Medical Virology

    Volume 75, Issue 3, March 2005, Pages: 391–398, Jian Sun, Zhanhui Wang, Shiwu Ma, Guobing Zeng, Zhiyong Zhou, Kangxian Luo and Jinlin Hou

    Version of Record online : 12 JAN 2005, DOI: 10.1002/jmv.20281

  6. Abstract Index

    Journal of Gastroenterology and Hepatology

    Volume 19, Issue s7, December 2004, Pages: A676–A868,

    Version of Record online : 3 DEC 2004, DOI: 10.1111/j.1440-1746.2004.03735.x

  7. You have free access to this content
    Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy

    Hepatology

    Volume 34, Issue 4, October 2001, Pages: 785–791, Man-Fung Yuen, Erwin Sablon, Prof. Chee-Kin Hui, He-Jun Yuan, Hilde Decraemer and Ching-Lung Lai

    Version of Record online : 30 DEC 2003, DOI: 10.1053/jhep.2001.27563

  8. Management of Drug-Resistant Mutants

    Viral Hepatitis, Third Edition

    Howard Thomas, Stanley Lemon, Arie Zuckerman, Pages: 337–344, 2007

    Published Online : 26 OCT 2007, DOI: 10.1002/9780470987131.ch21

  9. YMDD mutants in patients with chronic hepatitis B before treatment are not selected by lamivudine

    Journal of Medical Virology

    Volume 74, Issue 2, October 2004, Pages: 361–366, Marie Matsuda, Fumitaka Suzuki, Yoshiyuki Suzuki, Akihito Tsubota, Norio Akuta, Tetsuya Hosaka, Takashi Someya, Masahiro Kobayashi, Satoshi Saitoh, Yasuji Arase, Junko Satoh, Mariko Kobayashi, Kenji Ikeda, Yuzo Miyakawa and Hiromitsu Kumada

    Version of Record online : 20 AUG 2004, DOI: 10.1002/jmv.20185

  10. APASL Abstracts, Bali 2005

    Liver International

    Volume 25, Issue 6, December 2005, Pages: 1270–1384,

    Version of Record online : 11 NOV 2005, DOI: 10.1111/j.1478-3231.2005.01182.x

  11. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B

    Journal of Gastroenterology and Hepatology

    Volume 19, Issue 11, November 2004, Pages: 1276–1282, TING-TSUNG CHANG, CHING-LUNG LAI, RONG-NAN CHIEN, RICHARD GUAN, SENG-GEE LIM, CHUAN-MO LEE, KENG-YEEN NG, GRAHAM J NICHOLLS, JULIE C DENT and NANCY WY LEUNG

    Version of Record online : 11 JUN 2004, DOI: 10.1111/j.1440-1746.2004.03428.x

  12. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C

    Journal of Viral Hepatitis

    Volume 14, Issue 11, November 2007, Pages: 767–774, X. P. Pan, L. J. Li, W. B. Du, M. W. Li, H. C. Cao and J. F. Sheng

    Version of Record online : 15 APR 2007, DOI: 10.1111/j.1365-2893.2007.00869.x

  13. Management of chronic hepatitis B virus infection: a new era of disease control

    Internal Medicine Journal

    Volume 36, Issue 2, February 2006, Pages: 100–113, G. C. Farrell and N. C. Teoh

    Version of Record online : 10 FEB 2006, DOI: 10.1111/j.1445-5994.2006.01027.x

  14. Viral Hepatitis

    Textbook of Hepatology: From Basic Science to Clinical Practice, Third Edition

    Mario Rizzetto, Fabien Zoulim, Pages: 819–956, 2008

    Published Online : 15 APR 2008, DOI: 10.1002/9780470691861.ch9a

  15. Favorable efficacy of long-term lamivudine therapy in patients with chronic hepatitis B: An 8-year follow-up study

    Journal of Medical Virology

    Volume 75, Issue 4, April 2005, Pages: 491–498, Norio Akuta, Fumitaka Suzuki, Yoshiyuki Suzuki, Hitomi Sezaki, Tetsuya Hosaka, Takashi Someya, Masahiro Kobayashi, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Mariko Kobayashi and Hiromitsu Kumada

    Version of Record online : 15 FEB 2005, DOI: 10.1002/jmv.20305

  16. You have free access to this content
    AASLD Abstracts

    Hepatology

    Volume 56, Issue S1, October 2012, Pages: 191A–1144A,

    Version of Record online : 1 OCT 2012, DOI: 10.1002/hep.26040

  17. You have free access to this content
    AASLD Abstract (pp. 162A–266A)

    Hepatology

    Volume 40, Issue S4, October 2004, Pages: 574A–675A,

    Version of Record online : 10 FEB 2006, DOI: 10.1002/hep.1840400507

  18. Changes in serum hepatitis B e antigen (HBeAg) levels associated with the emergence of YMDD mutants in HBeAg non-seroconverted patients during lamivudine therapy

    Liver International

    Volume 27, Issue 10, December 2007, Pages: 1349–1355, Yi-Hao Yen, Sheng-Nan Lu, Chien-Hung Chen, Jing-Houng Wang, Chun-Mei Wu, Chao-Hung Hung, Po-lin Tseng, Tsung-Hui Hu, Chi-Sin Changchien and Chuan-Mo Lee

    Version of Record online : 20 NOV 2007, DOI: 10.1111/j.1478-3231.2007.01609.x

  19. Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants

    Journal of Medical Virology

    Volume 78, Issue 3, March 2006, Pages: 341–352, Fumitaka Suzuki, Norio Akuta, Yoshiyuki Suzuki, Hitomi Sezaki, Yasuji Arase, Tetsuya Hosaka, Takashi Someya, Masahiro Kobayashi, Satoshi Saitoh, Kenji Ikeda, Mariko Kobayashi, Marie Matsuda, Junko Satoh, Sachiyo Watahiki and Hiromitsu Kumada

    Version of Record online : 17 JAN 2006, DOI: 10.1002/jmv.20546

  20. Correlation of YMDD mutation and breakthrough hepatitis with hepatitis B virus DNA and serum ALT during lamivudine treatment

    Hepatology Research

    Volume 40, Issue 2, February 2010, Pages: 125–134, Mariko Kobayashi, Fumitaka Suzuki, Norio Akuta, Hiromi Yatsuji, Tetsuya Hosaka, Hitomi Sezaki, Masahiro Kobayashi, Yusuke Kawamura, Yoshiyuki Suzuki, Yasuji Arase, Kenji Ikeda, Rie Mineta, Satomi Iwasaki, Sachiyo Watahiki and Hiromitsu Kumada

    Version of Record online : 25 SEP 2009, DOI: 10.1111/j.1872-034X.2009.00565.x